Delayed Nyse  -  04:00 2022-06-24 pm EDT
544.81 USD   +0.78%
06/14S&P Upgrades Thermo Fisher Scientific One Notch To 'A-' On Expected Leverage Below 3x and Strong Demand; Outlook Stable
06/14THERMO FISHER SCIENTIFIC : Ex-dividend day for
06/10Illumina Shares Drop 10% After CFO Departure
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific Introduces QualTrak Biopharma qPCR Solutions to Streamline Biologics Development and Compliance

05/10/2022 | 08:00am EDT

Thermo Fisher Scientific launched a new collection of qPCR biopharma offerings to help accelerate drug development to meet a growing demand for novel biologics. The QualTrak comprehensive suite of qPCR tools is comprised of a premium selection of trusted Applied Biosystems solutions, including QuantStudio 6 and 7 Pro Real-Time PCR Systems and TaqMan and TaqPath master mixes and assays, to consistently and accurately support the biopharma industry from discovery to post-approval manufacturing. QualTrak solutions come with readily available compliance documentation to reduce the time required to comply with internal quality systems and regulatory requirements. The carefully curated selection of high-quality qPCR master mixes, assays, instruments, and software are backed by world-class service and support to help simplify drug filings. To support post-discovery steps such as manufacturing QC and biodistribution where reliable results and regulatory compliance are critical, QualTrak TaqPath master mixes and assays are manufactured at an ISO 13485-certified, U.S. Food and Drug Administration registered facility that adheres to cGMP manufacturing requirements and demonstrates exceptional lot-to-lot consistency. With its vertically integrated supply chain and extensive logistics network, Thermo Fisher is positioned to support growing global demand for biopharma-specific qPCR solutions. In addition, for the first time customers can easily and quickly sign up to be notified of product changes without entering into a supply agreement. To complement the new offerings, Thermo Fisher is introducing a new downloadable app highlighting qPCR workflows and products for specific use cases across monoclonal antibodies, vaccines, and cell and gene therapies development pipelines. Until now, scientists had to navigate multiple websites to find biopharma-specific qPCR products for their biologics development. With the launch of the first-of-its-kind QualTrak app, customers have a central location to find the products and services they need. The new, interactive portal can quickly identify suggested PCR steps based on therapeutic modality and development phase, expediting product selection. To support biologic manufacturers' stringent quality control testing requirements, Thermo Fisher is also launching the Applied Biosystems TaqPath BactoPure master mix for consistent low-level microbial detection. This new qPCR master mix can detect as low as one copy of DNA per microliter from bacterial, viral, fungal, and mammalian sources, helping to ensure contamination-free drug products and accurate titers. Manufactured at an ISO 13485-certified and FDA-registered cGMP facility, BactoPure delivers superior lot-to-lot consistency and sensitivity, even in the presence of inhibitors. The exceptional performance of the TaqPath BactoPure Master Mix also makes it a valuable tool for assay developers in infectious disease testing labs to identify bacterial, viral, fungal DNA, and antibiotic resistance markers in clinical research samples.

© S&P Capital IQ 2022
06/14S&P Upgrades Thermo Fisher Scientific One Notch To 'A-' On Expected Leverage Below 3x a..
06/14THERMO FISHER SCIENTIFIC : Ex-dividend day for
06/10Illumina Shares Drop 10% After CFO Departure
06/09Illumina Says CFO Sam Samad to Depart July 8
06/09Thermo Fisher Scientific Inc Announces FDA Clears Thermo Scientific EliA RNA Pol III an..
06/09Thermo Fisher Scientific Tests Get FDA Clearance
06/07Thermo Fisher Scientific Inc. Updates Applied Biosystems QuantStudio 5 Dx Real-Time PCR..
06/06Thermo Fisher Scientific Inc. Showcases Solutions for Accelerating Next Generation Vacc..
06/06Thermo Fisher Scientific Showcases Solutions for Accelerating Next Generation Vaccine a..
06/06Thermo Fisher Scientific Collaborates with TransMIT GmbH on a High-Performance Orbitrap..
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 42 489 M - -
Net income 2022 6 837 M - -
Net Debt 2022 25 165 M - -
P/E ratio 2022 31,6x
Yield 2022 0,22%
Capitalization 213 B 213 B -
EV / Sales 2022 5,61x
EV / Sales 2023 5,33x
Nbr of Employees 130 000
Free-Float 88,7%
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 23
Last Close Price 544,81 $
Average target price 661,95 $
Spread / Average Target 21,5%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors